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a b s t r a c t
Transcatheter aortic valve implantation (TAVI) has revolutionized the management of
elderly patients with symptomatic severe aortic stenosis in the western world. It is a
valuable alternative to surgical aortic valve replacement in patients, who are inoperable
or at high surgical risk due to co-morbidities. The prevalence of aortic stenosis increases
sharply with age after the sixth decade and is expected to have a signiﬁcant impact on the
geriatric health care system of India, given the rapid increase in life expectancy in recent
years. Although a decade has passed since the ﬁrst TAVI implantation, it is yet to penetrate
most of the developing countries in a major way. This short review focuses on fundamentals
of initiating a TAVI program based on the experience of a high volume TAVI center with a
successful program in Germany.
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Rheumatic heart disease forms the major burden of valvular
heart disease in developing countries.1–3 However, age related
degeneration of the aortic valve is the most common cause of
isolated acquired aortic stenosis (AS) in developed and
developing countries alike.1,3 In an Indian hospital-based
echocardiographic survey, prevalence of isolated AS was as
high as 7.3%, with the vast majority of subjects being 60 years
and above.3 Studies on valvular heart disease in elderly from
developing nations are few and hence most of the prevalence
data are derived from western studies. The estimated
prevalence of AS increases with age, being present in 2% of* Corresponding author.
E-mail address: drjohnjose@gmail.com (J. Jose).
http://dx.doi.org/10.1016/j.ihj.2015.12.006
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).the adults above the age of 65 years and increases up to 12.4%
for those above the age of 75 years.5 The prevalence of
symptomatic severe AS in the elderly is 3.4%.5 The recent
decade has witnessed a steady increase in life expectancy in
India due to improved nutrition, health facilities and living
conditions. According to a United Nations report, India had 10
million persons above the age of 80 years in 2013.6 Based on
recent Indian demographics proﬁle data, 5–6% of the total
population of 1.25 billion (approximately 70 million people) are
above the age of 65 years.7 Extrapolating western prevalence
data to the Indian population, nearly 300,000 patients with AS
are likely to be eligible for transcatheter aortic valve
implantation (TAVI), a percutaneous procedure that has
transformed care of high risk or inoperable AS in the elderly.B.V. This is an open access article under the CC BY-NC-ND license
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beneﬁt from TAVI is slightly more than the combined number
of TAVI eligible patients in Europe and North America
estimated using a multiple Monte Carlo simulation model.5
TAVI program was introduced at the Segeberger Kliniken,
Germany in 2007, and over 600 implantations have been
performed since then, with excellent procedural success and
outcomes. A successful procedure relies on multiple factors
such as appropriate patient selection involving a multidisci-
plinary 'Heart Team', meticulous planning, and maintaining
high standards of care during and after the procedure (Table 1).
By this short review, we hope to provide some insight into
successful implementation of a TAVI program based on our
experience.
2. Hurdles for starting a TAVI program
Cost concerns and regulatory body approval are the two main
challenges for starting a TAVI program in the developing
world.
One of the major hurdles for starting a TAVI program is the
prohibitantly high device and procedure related costs that can
be as high as 12–15 lakhs Indian rupees (15,000–20,000 US $). At
current costs, it is certainly a mammoth task for any
government to support such an expensive program for the
entire country. Technological advancements and procedural
simpliﬁcation, availability of locally manufactured devices
and increase in volume of cases performed may ultimately
reduce the overall cost of a TAVI procedure. Till then,
alternative means of dedicated funding for a TAVI program
need to be actively pursued, which could be in the form of
institutional funding, support from research organizations
or public funding by charitable societies. Alternatively,
the government could identify limited regional centers ofTable 1 – Steps to set up a TAVI program.
Regulatory body approval
Identiﬁcation of TAVI capable centers and funding
TAVI training
Didactic lectures, simulator training, live case observations
'Mini fellowship' at high volume centers





Availability of CT, MRI and transesophageal
echocardiography
Spacious and sterile room – Hybrid operative theater or
dedicated catheterization lab with high quality imaging
availability
Availability of experienced echocardiographer
Capable of emergency heart surgery
Availability of bail out materials – coronary and peripheral
stents
Facilities for renal support if necessary
Capability of dedicated post-procedure care
TAVI program evaluation through registriesexcellence having necessary infrastructure and allocate
funds to perform a certain number of procedures annually.
Currently, India has still to get approval for a TAVI program
from its regulatory body although procedures have been
performed through individual license. Ever growing data from
TAVI trials on the beneﬁts and effectiveness of the procedure
supplemented by reports on cost effectiveness from indepen-
dent experts could accelerate the process of regulatory body
approval.
It is likely that volumes of TAVI cases performed in some
centers will be low, which has implications for efﬁcacy and
safety outcomes, as there appears to be a 'learning curve' for
operators. However, contrary to the popular belief, the
learning curve for TAVI is not too steep or long, and several
institutions have implemented the program successfully.
Nevertheless, during initial years of implementation of a
nationwide TAVI program, it may be prudent to limit the
number of centers performing TAVI in order to maintain a
sufﬁcient volume of procedures in each center.
It is also important to educate wider medical fraternity
regarding TAVI in the form of seminars or discussions with
general practitioners, physicians as well as ethical use of
media to disperse knowledge in the community.
3. TAVI training
Multisocieties (Society for Cardiovascular Angiography and
Interventions, American Association for Thoracic Surgery,
American College of Cardiology Foundation, and Society of
Thoracic Surgeons) have jointly identiﬁed operator and
institutional requirements for performing TAVI.8 TAVI opera-
tors should have wide ranging knowledge of aortic valvular
heart disease and its natural history, diagnostics and
hemodynamics, medical and surgical therapy, and their
outcomes. They should also have sufﬁcient echocardiographic
skills and expertise in interpreting computed tomography
scans of the iliofemoral vessels and aortic valvular anatomy. It
is also important to have experience with a variety of
interventional techniques including coronary and peripheral
diagnostic procedures and interventions, balloon valvuloplas-
ties, aortic endovascular repairs and large vessel access
closures. Consensus statement recommends a prior experi-
ence of 400 percutaneous coronary interventions per year with
acceptable outcomes for centers and 100 structural procedures
for operators, as prerequisite skills for performing TAVI.8 For
surgeons, 100 aortic valve replacement during their career (at
least 10 of which are high risk) or 25 per year and at least 20 in
the last year prior to TAVI initiation, are recommended.8
The device companies involved in the manufacture of
prostheses have a structured training and proctoring program
for TAVI teams, which is usually provided at one of the high
volume centers around the world. Operator aspirants are
usually provided with a 'training package' which consists of
educational material, case studies, screening advice and
materials, and instructions for device handling. On site
training usually involves interactive lectures, simulations
and live case observations. These sessions usually focus on
patient selection, procedural steps, complications, and trou-
bleshooting. Metric-based simulations are also provided by
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high volume center prior to the proctored training phase may
be useful in acquiring proper foundation skills necessary for
performing TAVI. On site proctor services may also be
available for certain centers with aims to ensure procedural
success and safety. After a certain adequate number of
proctored cases, the trainee may start performing TAVI
independently or in some instances, further training may be
recommended by the proctor in order to perform the
procedure without supervision. Clinical support for an
additional 10 or 12 cases following proctoring phase are
sometimes provided. Once a trainee is ﬁt to perform the
procedure independently, it is important not to have a long gap
between the training and start of the TAVI program.
4. 'Heart Team' approach
One of the important essentials for a successful TAVI program
is the selection of the most appropriate patient for TAVI. At our
German center, we follow a multidisciplinary heart team
approach, which involves cardiologists, angiologists, cardio-
thoracic surgeons, anesthetists, intensive care specialists,
and importantly patients themselves. Elderly patients with
symptomatic severe AS often have signiﬁcant associated co-
morbidities, and predictive scores such as the EuroScore and
Society of Throacic Surgeons' score are valuable for therapy
selection. All patients are assessed and thoroughly investigat-
ed by blood tests, echocardiography, right and left heart
catheterization, and CT Imaging prior to discussion at the
heart team conference. During the heart team meet, decision
regarding the access route for TAVI (trans-femoral versus
trans-apical or trans-aortic routes) is also arrived at if a patient
is planned for TAVI.
5. TAVI procedure
5.1. Technique
TAVI is performed in a hybrid operating suite in our center,
although it is possible to perform the procedure in a routine
angiography lab, provided it has sufﬁcient space needed to
accommodate device preparation, echocardiographic device,
anesthetic machine, and surgical set-up including certain
speciﬁcations for a sterile environment. The majority of TAVI
procedures are performed through the trans-femoral route.
Almost all of our trans-femoral TAVI procedures are done
under conscious sedation with general anesthesia reserved for
those with compromised hemodynamics or patient prefer-
ence. With conscious sedation, we have observed better
hemodynamic status, lesser need for ionotropes, shorter
procedural duration and length of intensive care unit stay.
We perform the procedure without transesophageal echocar-
diography (TEE) guidance. However, some centers do perform
intra-procedural TEE. Use of intraprocedural TEE is associated
with disadvantages that can potentially outweigh its beneﬁts.
TEE usually requires general anesthesia, and severe AS
patients are known to tolerate hypotension poorly. TEE probe
may also partially obstruct the ﬂuoroscopic view necessitatingmultiple retractions and advancements of the TEE probe
during the procedure. However, TEE guidance is beneﬁcial in
patients with limited native valve calciﬁcations and valve-in-
valve procedures especially involving a stentless surgical
bioprosthesis. A temporary pacing catheter (balloon tipped or
helical screw temporary lead) is always positioned in the right
ventricle prior to the procedure, usually through the right
jugular route. External deﬁbrillator pads and venous access
lines are also placed. For trans-femoral TAVI, both groins are
used for vascular access – a 6 or 7F access for a pigtail catheter
on one side, and contralaterally, an initial 10F sheath which is
later upgraded to the larger TAVI introducer sheath. Single
Proglide (Abbott Vascular, Santa Clara, CA, USA) pre-sutures
are laid on the side used for TAVI device. After aortography,
the aortic valve is crossed by a guidewire followed by
measurement of pressure gradients. Balloon dilatation if
required is performed using an undersized balloon under a
brief period of rapid ventricular pacing.
Prosthesis preparation is done simultaneously by another
operator or an assistant. Annulus size and optimal angio-
graphic projection for device implantation is predetermined
from the information obtained from computed tomography
(CT). Some operators recommend a minimum distance of
10 mm between the valve cusp hinge point and the coronary
ostium on CT to perform TAVI. However, this should not be
stressed as an absolute requirement, and factors such as sinus
width, leaﬂet size, and calciﬁcation are also taken into
consideration.
Balloon expandable valves are always deployed under rapid
ventricular pacing. Aortic valve gradients are then again
measured along with angiographic and transthoracic echo-
cardiographic assessments for leaks. Post-dilatation is per-
formed in case of signiﬁcant leaks. The catheters and
guidewires are withdrawn, and hemostasis achieved using
the Proglide suture (Abbott Vascular). It is essential to have
bailout materials such as snares, coronary guidewires, coro-
nary and peripheral stents in the room where TAVI is
performed.
An optimal TAVI program should incorporate other routes
for the TAVI procedure such as trans-apical, trans-aortic or
trans-subclavian, which may be necessary in the event of
small femoral access vessels or severe peripheral artery
diseases. For the trans-apical procedure, anterolateral mini
thoracotomy is performed and the valve delivered through a
sheath that is inserted via the apical puncture site.
6. Devices
Currently several devices have Conformité Européene mark
approval for use in Europe. All these devices can be classiﬁed
into one of balloon-expandable, self-expanding or differential
deployment device categories (Fig. 1).9 Of these devices,
SAPIEN 3 and CoreValve Evolut are in widespread clinical
use, and there are several others in early clinical trials phase.
The newer generation devices have low proﬁle delivery
systems (as low as 14F) to reduce access site complications,
design modiﬁcations to reduce paravalvular leaks, and some
are even capable of repositionability or retrievability. Direct
comparison studies between different classes of TAVI devices
Fig. 1 – Transfemoral TAVI devices.
Pictures provided courtesy of Edwards Lifesciences, Irvine, CA, USA; Medtronic, Minneapolis, MN, USA; Symetis SA,
Ecublens, Switzerland; St. Jude Medical, St. Paul, MN, USA; Direct Flow Medical Inc., Santa Rosa, CA, USA and Boston
Scientific, Marlborough, MA, USA. Modified and reprinted from ‘‘Abdel-Wahab M, Jose J, Richardt G. Transfemoral TAVI
devices: design overview and clinical outcomes. EuroIntervention. 11(suppl. W):W118–W122. Copyright (2015) with
permission from Europa Digital & Publishing’’.
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the only trial directly comparing balloon-expandable and self-
expanding devices.10 One year outcomes of this trial showed
no signiﬁcant difference in clinical outcomes despite higher
post-procedural device success with balloon-expandable
valves (SAPIEN XT; Edwards Lifesciences, Irvine, CA, USA).
However, the self-expanding valve (CoreValve; Medtronic,
Minneapolis, MN, USA) was associated with higher rates of
paravalvular regurgitation.11 There are no long-term random-
ized trials comparing newer generation devices.
7. Post-procedural care
In our center, all patients are transferred to the Intensive Care
Unit (ICU) after the procedure, and monitored for hemody-
namic and electrocardiographic parameters. When the level
of care required is deemed to be lower, those with uneventful
ICU stay are discharged to the ward. A transthoracicechocardiography is performed prior to discharge and
follow-up visits are scheduled at 1 month, 6 months, 1 year
and yearly thereafter. Patients with uncomplicated proce-
dures and hospital stay are usually discharged within a few
days after TAVI. All patients are offered a further rehabilita-
tive program after discharge.
TAVI patients are routinely discharged on dual antiplate-
lets. Those who require oral anticoagulation are discharged on
a single antiplatelet drug. For those with increased bleeding
risk and requiring oral anticoagulation, we tend to perform left
atrial appendage closure followed by dual antiplatelet drugs.
8. TAVI program evaluation
Once a TAVI program is in place, it is necessary to have
performance monitoring measures in order to recognize
shortcomings of the program as well as to evaluate procedure
outcomes. Follow-ups are typically scheduled at 30 days,
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during follow-up are clinical and echocardiographic, and
outcomes are reported in accordance with updated Valve
Academic Research Consortium-2 (VARC-2) standardized
endpoint deﬁnitions.12 Currently, there is limited long-
term data on survival outcomes, quality of life and cost
effectiveness in comparison to surgical management. It is
therefore necessary to maintain a database of all TAVI
procedures from the onset of the program in order to track
outcomes after the procedure. Prospective cohort studies and
randomized controlled trials can add to the wealth of
knowledge subsequently.
9. Summary
The use of TAVI has increased exponentially in recent years in
the western world and is poised to navigate the uncharted
waters of the developing world in the near future. There seems
to be a sizeable number of at demand elderly AS patients in
India, who are deprived of this beneﬁcial procedure owing to
its current high costs and non-availability. Epidemiological
studies are however needed to estimate the actual number of
patients who might beneﬁt from TAVI. A successful TAVI
program provides hope to inoperable and high-risk AS patients
and is an incredibly rewarding experience for operators as
well. Centers with prior experience in structural interventions,
endovascular repairs, and surgical valve replacements could
pool resources and personnel to form a 'Heart Team', who
would then undergo structured training for a TAVI program.
India has the necessary infrastructure, but cheaper devices
and innovative programs tailored to the needs of the country
are keys to the successful implementation of a TAVI program.
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